(Q45196382)

10 December 2017

title

A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma (English)

1 reference

10 December 2017

main subject

phase I clinical trial

0 references

1 reference

3

Eric J Small

1 reference

10 December 2017

Brian I Rini

1

1 reference

10 December 2017

Vivian Weinberg

series ordinal

2

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

10 December 2017

1 reference

10 December 2017

volume

103

1 reference

10 December 2017

issue

3

1 reference

10 December 2017

page(s)

553-558

1 reference

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Gemcitabine: a phase II study in patients with advanced renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20795

7 January 2021

Identifiers

DOI

10.1002/CNCR.20795

1 reference

10 December 2017

1 reference